Nat Cancer October 2025 PMID 40696154

CAR-engineered lymphocyte persistence is governed by a FAS ligand-FAS autoregulatory circuit.

Fei Yi, Tal Cohen, Natalie Zimmerman, Friederike Dündar, Paul Zumbo, Razan Eltilib, Erica J Brophy, Hannah Arkin, Judith Feucht, Michael V Gormally, Christopher S Hackett, Korbinian N Kropp, Inaki Etxeberria, Smita S Chandran, Zeguo Zhao

Mentions

38
Peak: 14 in Jul 2025
across 5 sources since Mar 2024

Extended reach

89,499
potential audience

Total likes

53

Video views

41

Mentions per month

Mar 2024 – Aug 2025

Where it's discussed

  • X / Twitter19 posts
  • YouTube8 videos
  • Bluesky5 posts
  • News3 articles
  • Blogs3 articles

AI synopsis

What people are saying

The collective digital discussions demonstrate strong interest and moderate engagement, with examples including posts praising the findings, such as 'Congrats on this important breakthrough,' and technical comments analyzing the role of FAS-L. The tone reflects both excitement about the scientific advances and some skepticism about the translational impact, highlighting the overall significance of the research in advancing immunotherapy.

AgreementModerate agreement

Most discussions affirm the significance of the research, with many expressing support or congratulations, indicating general agreement on its importance.

InterestHigh interest

Participants show high curiosity, often referencing the potential implications for CAR therapy and the detailed mechanisms involved.

EngagementModerate engagement

Posts engage with specific aspects of the study, such as the role of FAS-L in lymphocyte persistence, with some reflecting on the methodology or scientific implications.

ImpactModerate impact

The discussions suggest the research could influence future immunotherapy approaches, though some are skeptical about the immediate practical applications.

Abstract in brief

  • CAR-engineered lymphocytes show promise in treating B cell cancers, but their effectiveness is limited by their inability to persist long-term in the body.
  • Researchers created a single-cell atlas to identify sources of FAS ligand (FAS-L), finding it mainly expressed in T cells, NK cells, and CAR-T cells, with minimal expression in tumors and stroma.
  • Experiments demonstrated that modifying CAR-T and CAR-NK cells to resist FAS-L led to enhanced survival and antitumor effects, highlighting the role of FAS-L in regulating CAR lymphocyte persistence while noting that FAS-L isn't crucial for their ability to kill tumors.

Top posts

Most liked on X and Bluesky
Nature Cancer
@NatureCancer · X

Jul 30, 2025 · 26 likes · 7 shares · 37,700 followers View post →
bioRxiv Immunology
@biorxiv_immuno · X

CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuit https://t.co/B22C43lEl7 #biorxiv_immuno

Mar 1, 2024 · 11 likes · 4 shares · 10,583 followers View post →
Nature Cancer
@natcancer.nature.com · Bluesky

Jul 30, 2025 · 5 likes · 1 share View post →
Wafik S. El-Deiry, MD, PhD, FACP
@weldeiry · X

CAR-engineered lymphocyte persistence is governed by a FAS ligand–FAS autoregulatory circuit https://t.co/EOGotqZtZW

Jul 23, 2025 · 4 likes · 18,060 followers View post →
Yoshihisa Okazaki
@XX62 · X

『CAR-engineered lymphocyte persistence is governed by a FAS ligand–FAS autoregulatory circuit』 Nature Cancer  22 July 2025 FAS-L/FASがリンパ球寿命を制御 ΔFAS(FASのドミナントネガティブ変異)導入すると: CAR-T/NK細胞は長く生きる ΔFASの導入はマウスモデルで抗腫瘍効果を高めた https://t.co/S33lK5maY6

Aug 4, 2025 · 4 likes · 2,282 followers View post →
bxv_imm
@bxv_imm · X

CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuit https://t.co/yh9Acjf451 https://t.co/yx2IhcrxCF

Mar 1, 2024 · 2 likes · 440 followers View post →

All mentions

Yoshihisa Okazaki
@XX62 · X

『CAR-engineered lymphocyte persistence is governed by a FAS ligand–FAS autoregulatory circuit』 Nature Cancer  22 July 2025 FAS-L/FASがリンパ球寿命を制御 ΔFAS(FASのドミナントネガティブ変異)導入すると: CAR-T/NK細胞は長く生きる ΔFASの導入はマウスモデルで抗腫瘍効果を高めた https://t.co/S33lK5maY6

Aug 4, 2025 · 4 likes · 2,282 followers View post →
Inaki Etxeberria
@etxeberria_i · X

RT @NatureCancer:

Aug 1, 2025 · 7 shares · 50 followers View post →
Martin Correa
@martinrafco · X

RT @NatureCancer:

Jul 31, 2025 · 7 shares · 231 followers View post →
Khalil Zayed
@AgingPioneer · X

RT @NatureCancer:

Jul 31, 2025 · 7 shares · 5 followers View post →
Maria-Jose Felgueres Planells, PhD
@MJ_Felgueres · X

RT @NatureCancer:

Jul 31, 2025 · 7 shares · 70 followers View post →
AngryPhDstudent❗️❗️❗️
@ONNESHA092 · X

RT @NatureCancer:

Jul 31, 2025 · 7 shares · 188 followers View post →
Klebanoff_Lab
@KlebanoffLab · X

RT @NatureCancer:

Jul 30, 2025 · 7 shares · 3,194 followers View post →
Youssef Nader
@lifewithyn · X

RT @NatureCancer:

Jul 30, 2025 · 7 shares · 19 followers View post →
Nature Cancer
@natcancer.nature.com · Bluesky

Jul 30, 2025 · 5 likes · 1 share View post →
Nature Cancer
@NatureCancer · X

Jul 30, 2025 · 26 likes · 7 shares · 37,700 followers View post →
Ordo Fraterna Fibonacci
@OrdoFibonacci · X

CAR-engineered lymphocyte persistence is governed by a FAS ligand–FAS autoregulatory circuit Nature https://t.co/N6qMTMKemS

Jul 24, 2025 · 2,569 followers View post →
Ordo Fraterna Fibonacci
@ordofibonacci.bsky.social · Bluesky

CAR-engineered lymphocyte persistence is governed by a FAS ligand–FAS autoregulatory circuit Nature www.nature.com/articles/s43...

Jul 24, 2025 View post →
Topaz
@Topaz20211 · X

@weldeiry Consider not promoting Nature, who in turn promote the retratraction mob. Consider Pubmed links instead: https://t.co/YCZ29tYq0t Never forget: https://t.co/0lPTja98AD

Jul 23, 2025 · 435 followers View post →
Wafik S. El-Deiry, MD, PhD, FACP
@weldeiry.bsky.social · Bluesky

CAR-engineered lymphocyte persistence is governed by a FAS ligand–FAS autoregulatory circuit www.nature.com/articles/s43...

Jul 23, 2025 View post →
Wafik S. El-Deiry, MD, PhD, FACP
@weldeiry · X

CAR-engineered lymphocyte persistence is governed by a FAS ligand–FAS autoregulatory circuit https://t.co/EOGotqZtZW

Jul 23, 2025 · 4 likes · 18,060 followers View post →
Naile-Ila Koleci
@naile_ila · X

RT @biorxiv_immuno: CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuit https://t.co/B22C43lEl7…

Mar 2, 2024 · 4 shares · 35 followers View post →
Vince Beltran, Ph.D.
@levin_beltran · X

RT @biorxiv_immuno: CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuit https://t.co/B22C43lEl7…

Mar 2, 2024 · 4 shares · 11,762 followers View post →
Tomasz Grzywa, MD, PhD
@drtomaszgrzywa · X

RT @biorxiv_immuno: CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuit https://t.co/B22C43lEl7…

Mar 1, 2024 · 4 shares · 376 followers View post →
Thaminda Ramanayake
@thaminda19 · X

Congrats @KlebanoffLab and team! CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuit https://t.co/niJLOQyNO1

Mar 1, 2024 · 1 like · 1,022 followers View post →
bxv_imm
@bxv_imm · X

CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuit https://t.co/yh9Acjf451 https://t.co/yx2IhcrxCF

Mar 1, 2024 · 2 likes · 440 followers View post →
Vladislav Sergeev
@DrVladSergeev · X

RT @biorxiv_immuno: CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuit https://t.co/B22C43lEl7…

Mar 1, 2024 · 4 shares · 285 followers View post →
bioRxiv Immunology
@biorxiv-immuno.bsky.social · Bluesky

CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuit https://www.biorxiv.org/content/10.1101/2024.02.26.582108v1

Mar 1, 2024 View post →
bioRxivpreprint
@biorxivpreprint.bsky.social · Bluesky

CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuit https://www.biorxiv.org/content/10.1101/2024.02.26.582108v1

Mar 1, 2024 View post →
bioRxiv Immunology
@biorxiv_immuno · X

CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuit https://t.co/B22C43lEl7 #biorxiv_immuno

Mar 1, 2024 · 11 likes · 4 shares · 10,583 followers View post →